All News
Cardiovascular Events: Allopurinol vs. Febuxostat
In the registration trials for febuxostat there were concerns about a cardiovascular (CV) safety signal. In studies of the effect of allopurinol on CV risk/events allopurinol has found to be protective so whether febuxostat is different is a point to clarify.
Read Article
EULAR/ACR SLE Classification Criteria Update
Today the draft of the new EULAR/ACR lupus classification criteria was presented at the ACR 2017.
Read Article
Comparative Risk of Biologic Therapies in RA Patients Undergoing Elective Arthroplasty
During today’s plenary session Micheal D. George, et al. presented results of a study that sought to compare risk of post-op infections in RA patients undergoing arthroplasty exposed to biologic DMARDs versus methotrexate.
Read Article
2017 MIPs Reporting, What You Need to Know
As a follow up to Dr. Will Harvey’s lecture at ACR 2017 (session title: Holy MACRA! How to Survive and Thrive in the New Era of MACRA, MIPS, and APMs), here are the keys for reporting your collections.
Read Article
IL-17 Inhibition with Secukinumab in PsA: X-Ray Outcomes
With the emergence of new MOAs for the treatment of psoriatic arthritis in recent years, the most burning question remained if newer agents would perform as well in terms of radiographic progression as they did in clinical domains.
Read Article
Who Are We Doing This For?
We take many things for granted. I walked 11,151 steps today going from sessions to posters and exhibit halls to learn as much as I can to take back to my clinic so I can help my patients. My feet were hurting, and my back bothered me as I tried to get comfortable for the next lecture; yet, these minor discomforts are nothing compared to what our patients experience on a daily basis.
Read Article
Podcast of ACR17 Day 2
Check out this compilation of our ACR17 Day 2 videocasts merged into a one hour podcast !
Read Article
ACR 2017 - Day 2 Highlights
In the afternoon on Monday, the ACR ran a clinical symposium on gout. One presentation stood out, on “Asymptomatic hyperuricemia” (AH) by M. Pillinger, MD from NYU Medical School. At issue is when should AH be treated.
Read Article
Kidney transplant improves survival in GPA
Even with currently available treatment modalities, ESRD is a common complication of Granulomatosis with polyangiitis (GPA) occurring in approximately 25% of patients. Transplantation frequently used for ESRD but has not been applied widely in GPA.
SLE Clinical Trial Design and Outcome Measures
Clinical trials remain a challenge in SLE and a number of outcome measures have been used with varying success.
Two abstracts in this session sought to address novel ways to assess responses in SLE trials.
Read Article
Tech Tools for Rheumatologists Version 3.0
Low-dose Bactrim Safe with Methotrexate in AAV
A high proportion of GPA patients receive pneumocystis prophylaxis, usually with TMP-SMX (Bactrim), and drug interactions are always a concern.
Read Article
Large Vessel Vasculitis: Giant Cell Arteritis and Takayasu Arteritis
Prof Weyland started by explaining that giant cell arteritis (GCA) and Takayasu Arteritis (TA) are granulomatous forms of arteritis.
Read Article
Gut-derived TNF: Connection Between Crohn’s and SpA and Sacroiliitis
The pathogenesis between microscopic gut inflammation leading to the development of Crohn’s disease and sacroiliitis has been poorly understood. Dr. Debusschere, et al sought to understand this important link between IBD and axial SpA.
Read Article
Co-morbid Fibromyalgia
Sustenance Inspector’s 2017 Annual ACR report
There are two things I learned in rheumatology fellowship.
Never burn any bridges because everyone in rheumatology knows each other
Rheumatologists like their food
Podcast of ACR Day 1
Check out this compilation of our ACR Day 1 videocasts merged into one 59 minute podcast !
https://soundcloud.com/rheumnow/rheumnow-acr-2017-san-diego-day-1
Read Article
ACR 2017 - Day 1 Highlights
Curtis and colleagues presented a plenary session that analyzed the duration of drug holidays and the risk of subsequent fractures (FX) in women starting bisphosphonates (BP).
Read Article
RA and Cardiac Co-Morbidities
We know that cardiovascular disease (CVD) is the leading cause of death in RA and that traditional risk factors do not fully account for increased risk.
Read Article